Navigation Links
Divine Skin (DSKX) Launches Health-Care Division To Develop New OTC and Prescription Drugs
Date:7/6/2010

Polaris Research makes high-potency minoxidil-based hair-growth formulas (www.polarisresearch.co.uk).

Divine Skin's management believes the company has established itself as a leader in topical therapies, especially hair-growth, through aggressive pursuit of innovation and technology. Products employ comprehensive formulas with multiple methods of action against common skin conditions. Many utilize proprietary encapsulation techniques for improved bioavailability.


'/>"/>
SOURCE Divine Skin Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
2. Watson Launches Generic Exelon®
3. United Seating & Mobility Launches New Company Website and E-Commerce Store at www.UnitedSeating.com
4. ePharmaSolutions Launches New Version of Electronic Monitor Visit Report Application With Industry-Leading Online and Offline Capabilities
5. DHL Global Mail Launches Specialized Shipping Service for Mail-Order Pharmacies
6. National Eye Institute Launches Ancillary Study to AREDS2 With ForeseeHome(TM) AMD Monitor
7. MedAvante Launches Service to Boost Reliability of Assessments to Reduce Risk of Failed Alzheimers Disease Trials
8. Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.
9. CareFusion Launches First Automatic Oxygen Controller to Improve Care for Newborns Needing Mechanical Ventilation
10. Zargis Launches Telemedicine System with Real-Time Transmission of Stethoscope Sounds
11. Ankota Launches Real-Time Family Communication Tool Tracking Health of Loved One
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , España, September 2, 2014 ... de fibrilación atrial muestran agentes antitrombóticos no utilizados ... -- Las presentaciones de GARFIELD-AF en ... el tratamiento y los resultados de pacientes en ... diaria --    Los datos de ...
(Date:9/2/2014)... , September 2, 2014 ... ESC CONGRESS 2014 provide insight into treatment and ... everyday clinical practice --   Data ... Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an ... stroke prevention strategies for atrial fibrillation (AF) patients ...
(Date:9/2/2014)... 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... of the company at the Morgan Stanley Global Healthcare Conference ... Presentation date: Tuesday September 9, 2014 , Presentation time: ... and 30-day archive of this presentation will be available at ... Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused ...
Breaking Medicine Technology:Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... (Nasdaq:  ARAY), a global leader in the field of ... institutions using CyberKnife radiosurgery in breast cancer treatment. These ... Fox Chase Cancer Center, will be presented at the ... Oncology (ASTRO) in San Diego from October 31 to ...
... 2010 Boehringer Ingelheim Pharmaceuticals, Inc. announced today results ... combination of two oral hepatitis C virus (HCV) compounds, ... BI 207127, with ribavirin reduced viral load below the ... The regimen did not include interferon through the first ...
Cached Medicine Technology:CyberKnife Radiosurgery for Early-Stage Breast Cancer 2CyberKnife Radiosurgery for Early-Stage Breast Cancer 3CyberKnife Radiosurgery for Early-Stage Breast Cancer 4CyberKnife Radiosurgery for Early-Stage Breast Cancer 5CyberKnife Radiosurgery for Early-Stage Breast Cancer 6Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon 2Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon 3Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon 4
(Date:9/2/2014)... New York, NY (PRWEB) September 02, 2014 ... and other new blood thinners is growing at a ... ) continue to mount in courts around the U.S., ... published in American Journal of Medicine, within a year ... to be prescribed Xarelto as warfarin, a blood thinner ...
(Date:9/2/2014)... Complications are rare among breast cancer patients who ... However, the researchers did find that a ... risk for certain complications than a single mastectomy. ... cancer patients who had a single (64 percent) ... were followed for 30 days after surgery. ...
(Date:9/2/2014)... In a large population-based study of randomly ... cognitive impairment (MCI) occurred twice more often in ... this strong association was only observed in middle-aged ... years) the association vanished. This study is published ... , The concept of MCI describes an intermediate ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Medex ... location of their corporate headquarters in Coral Springs, Fla. ... have exceeded our business development objectives for the 2014 ... Neil Herbst. “Our industry has requested a higher level ... utilization reviews. Medex has delivered, and the industry has ...
(Date:9/2/2014)... HealthDay Reporter TUESDAY, Sept. 2, ... driving force behind the rising rates of type 2 diabetes, ... from five national surveys spanning from 1976 through 2010 to ... be explained by factors such as changing distribution of race, ... that the prevalence of diabetes in men rose from about ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3
... , GLEN ALLEN, Va. , March 16 Star ... 10-K today with the Securities and Exchange Commission. The company reported net ... million in total sales for the previous year.  Cash and cash ... $6.5 million at year-end 2008. The net loss for 2009 totaled ...
... 16, 2010 The AIUM is pleased to ... AIUM to endorse the recent AIUM Training Guidelines ... guidelines allow for a several practitioners, including physicians, ... ultrasound examinations, marking significant promise for the future ...
... negative side effects, end-of-life care, review finds , ... that media reports slant towards bad news, but when ... may be overly optimistic, U.S. researchers suggest. , The ... highlight aggressive treatment and survival, with far less attention ...
... taking Plavix before surgery died soon after than those ... (HealthDay News) -- In a trial comparing two anti-clotting ... less likely to die than those given Plavix, researchers ... forming clots, but Plavix, the more popular drug, has ...
... GREENBELT, Md. , March 16 The following is being issued by LibertyProtection.net: , ... , , ... ... On ...
... Larry Minnix, President & CEO, American Association of Homes and Services for the Aging: , ... , , ... ... ...
Cached Medicine News:Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 2Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 3Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 4Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 5Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 6Health News:Unprecedented AIUM training guidelines speak to future of musculoskeletal ultrasound 2Health News:Cancer Articles Tend to Focus on Positive Outcomes 2Health News:Newer Blood Thinner Beats Plavix for Bypass Patients 2Health News:Newer Blood Thinner Beats Plavix for Bypass Patients 3Health News:Court Hearing Thursday on Physicians' Challenge to 'Obamacare': Doctors Argue Against 'Arbitrary Power and Tyranny' 2Health News:Court Hearing Thursday on Physicians' Challenge to 'Obamacare': Doctors Argue Against 'Arbitrary Power and Tyranny' 3Health News:Court Hearing Thursday on Physicians' Challenge to 'Obamacare': Doctors Argue Against 'Arbitrary Power and Tyranny' 4Health News:Statement From Larry Minnix, President & CEO, American Association of Homes and Services for the Aging, on the Beginning of the Reconciliation Process for Health Reform Legislation 2Health News:Statement From Larry Minnix, President & CEO, American Association of Homes and Services for the Aging, on the Beginning of the Reconciliation Process for Health Reform Legislation 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: